{
    "Trade/Device Name(s)": [
        "Alere\u2122 PBP2a Test",
        "Alere\u2122 PBP2a"
    ],
    "Submitter Information": "Alere Scarborough, Inc.",
    "510(k) Number": "K121905",
    "Predicate Device Reference 510(k) Number(s)": [
        "K091766"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MYI"
    ],
    "Summary Letter Date": "June 27, 2012",
    "Summary Letter Received Date": "June 29, 2012",
    "Submission Date": "June 27, 2012",
    "Regulation Number(s)": [
        "21 CFR 866.1640"
    ],
    "Regulation Name(s)": [
        "Antimicrobial susceptibility test powder"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Penicillin-binding protein 2a (PBP2a)"
    ],
    "Specimen Type(s)": [
        "Bacterial isolate (Staphylococcus aureus)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow assay"
    ],
    "Methodologies": [
        "Immunochromatographic testing",
        "Lateral flow"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for Alere PBP2a Test, a lateral flow immunochromatographic assay for detecting PBP2a in S. aureus isolates to aid in MRSA detection.",
    "Indications for Use Summary": "Qualitative, in vitro immunochromatographic assay for detection of PBP2a in S. aureus isolates as an aid in detecting MRSA; not intended for diagnosis or to guide/monitor treatment.",
    "fda_folder": "Microbiology"
}